Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH

Pediatr Blood Cancer. 2016 Feb;63(2):361-3. doi: 10.1002/pbc.25782. Epub 2015 Oct 21.

Abstract

Graft failure occurs at relatively low frequency, but commonly in hemophagocytic lymphohistiocytosis (HLH), especially with umbilical cord blood transplant (UCBT). No standard approaches to management of graft failure exist. We present a challenging case of relapsed HLH following first UCBT with primary graft failure following second UCBT. We report a novel reduced intensity conditioning regimen of alemtuzumab, 4 Gy total body irradiation and fludarabine for salvage of primary graft failure followed by double UCBT. The reported patient successfully engrafted with 100% donor chimerism following salvage UCBT with no occurrence of acute or chronic graft-versus-host disease.

Keywords: engraftment failure; hematopoietic stem cell transplantation; hemophagocytic lymphohistiocytosis; pediatric.

Publication types

  • Case Reports

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Combined Modality Therapy
  • Cord Blood Stem Cell Transplantation / methods*
  • Graft vs Host Disease
  • Humans
  • Infant
  • Lymphohistiocytosis, Hemophagocytic / therapy*
  • Male
  • Recurrence
  • Salvage Therapy / methods*
  • Transplantation Conditioning / methods*
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives
  • Whole-Body Irradiation / methods

Substances

  • Antibodies, Monoclonal, Humanized
  • Alemtuzumab
  • Vidarabine
  • fludarabine